<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Experimental and clinical evidence supports the notion that the Epstein-Barr virus (EBV) can become oncogenic in immune-deficient hosts </plain></SENT>
<SENT sid="1" pm="."><plain>Renal transplant recipients and children with inherited <z:hpo ids='HP_0002721'>immune deficiency</z:hpo> are at high risk for <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Defective immune responses to EBV permit persistence of polyclonal proliferation of B cells </plain></SENT>
<SENT sid="3" pm="."><plain>Conversion from polyclonal to monoclonal proliferation is probably the result of a cytogenetic error in a B cell </plain></SENT>
<SENT sid="4" pm="."><plain>This hypothesis can be tested prospectively in patients with <z:hpo ids='HP_0002721'>immune deficiency</z:hpo> by immunological, EBV, and genetic studies </plain></SENT>
</text></document>